Extracellular Vesicle Enriched miR-625-3p Is Associated with Survival of Malignant Mesothelioma Patients.
extracellular vesicles
mesothelioma
miR-625
prognosis
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
09 Oct 2021
09 Oct 2021
Historique:
received:
12
09
2021
revised:
03
10
2021
accepted:
07
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
Malignant mesothelioma (MM) is characterized by poor prognosis and short survival. Extracellular vesicles (EVs) are membrane-bound particles released from cells into various body fluids, and their molecular composition reflects the characteristics of the origin cell. Blood EVs or their miRNA cargo might serve as new minimally invasive biomarkers that would enable earlier detection of MM or treatment outcome prediction. Our aim was to evaluate miRNAs enriched in serum EVs as potential prognostic biomarkers in MM patients in a pilot longitudinal study. EVs were isolated from serum samples obtained before and after treatment using ultracentrifugation on 20% sucrose cushion. Serum EV-enriched miR-103-3p, miR-126-3p and miR-625-3p were quantified using qPCR. After treatment, expression of miR-625-3p and miR-126-3p significantly increased in MM patients with poor treatment outcome (
Identifiants
pubmed: 34683154
pii: jpm11101014
doi: 10.3390/jpm11101014
pmc: PMC8538530
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Slovenian Research Agency
ID : P1-170, L3-8203, L3-2622, and J3-9255
Références
Oncotarget. 2016 Sep 6;7(36):58606-58637
pubmed: 27259231
Nat Commun. 2016 Aug 16;7:12436
pubmed: 27526785
PLoS One. 2010 May 13;5(5):e10612
pubmed: 20485525
Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):9008-9013
pubmed: 30975761
PLoS One. 2012;7(6):e38248
pubmed: 22675530
Front Oncol. 2019 Aug 14;9:740
pubmed: 31475103
J Thorac Oncol. 2011 May;6(5):889-95
pubmed: 21358346
Mol Oncol. 2013 Jun;7(3):637-46
pubmed: 23506979
Drug Resist Updat. 2019 Dec;47:100647
pubmed: 31704541
Lancet. 2021 Jan 30;397(10272):375-386
pubmed: 33485464
Am J Pathol. 2013 Nov;183(5):1654-66
pubmed: 24160326
PLoS One. 2014 Dec 03;9(12):e114483
pubmed: 25469901
Biomed Res Int. 2018 Jun 5;2018:5724686
pubmed: 29967774
Oncotarget. 2016 Jun 14;7(24):36338-36352
pubmed: 27119351
Oncotarget. 2017 Jul 11;8(28):46425-46435
pubmed: 28507279
J Thorac Dis. 2018 Jan;10(Suppl 2):S353-S359
pubmed: 29507805
Lung Cancer. 2015 Dec;90(3):457-64
pubmed: 26431916
Oncogene. 2015 Feb 19;34(8):965-77
pubmed: 24632613
Oncotarget. 2015 Sep 29;6(29):27805-15
pubmed: 26314959
J Thorac Oncol. 2014 Nov;9(11):1662-8
pubmed: 25436799
Hepatoma Res. 2016 Nov;2:305-315
pubmed: 28393113
Front Oncol. 2020 Feb 21;10:187
pubmed: 32154179
Oncotarget. 2015 Dec 8;6(39):42053-66
pubmed: 26544728
Curr Oncol Rep. 2018 Mar 23;20(4):35
pubmed: 29572775
Nucleic Acids Res. 2020 Jan 8;48(D1):D148-D154
pubmed: 31647101
J Extracell Vesicles. 2017 Mar 7;6(1):1286095
pubmed: 28326170
Clin Biochem. 2012 May;45(7-8):575-81
pubmed: 22374169
Radiol Oncol. 2012 Jun;46(2):136-44
pubmed: 23077450
J Cell Mol Med. 2017 Nov;21(11):2663-2676
pubmed: 28470935
Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S100-S119
pubmed: 32206576
Dis Markers. 2017;2017:9280170
pubmed: 28321148
PLoS One. 2011 Apr 01;6(4):e18232
pubmed: 21483773
Cancer Cytopathol. 2016 Jan;124(1):28-37
pubmed: 26765063
J Thorac Dis. 2018 Jan;10(Suppl 2):S360-S368
pubmed: 29507806
Theranostics. 2018 Feb 7;8(6):1540-1557
pubmed: 29556340
J Surg Oncol. 2013 Sep;108(4):230-5
pubmed: 23861214
Cancer Lett. 2019 Oct 28;463:27-36
pubmed: 31400405
Carcinogenesis. 2015 Jan;36(1):76-81
pubmed: 25380601
Nucleic Acids Res. 2019 Jul 2;47(W1):W191-W198
pubmed: 31066453
J Clin Oncol. 2003 Jul 15;21(14):2636-44
pubmed: 12860938
Expert Rev Mol Diagn. 2015;15(7):907-23
pubmed: 25948243
Antioxid Redox Signal. 2014 Nov 20;21(15):2109-25
pubmed: 24444362
Cancer Cell Int. 2019 Dec 26;19:351
pubmed: 31889903
BMC Cancer. 2017 May 30;17(1):386
pubmed: 28558669
Sci Rep. 2019 Aug 12;9(1):11688
pubmed: 31406207
Am J Transl Res. 2019 Oct 15;11(10):6475-6486
pubmed: 31737199
Anticancer Drugs. 2012 Feb;23(2):230-8
pubmed: 22027538
Lung Cancer. 2009 Jun;64(3):308-13
pubmed: 19004520
Epigenomics. 2016 Nov;8(11):1449-1452
pubmed: 27779424
BMC Res Notes. 2019 Feb 11;12(1):77
pubmed: 30744695
J Extracell Vesicles. 2017 Aug 9;6(1):1347019
pubmed: 28815002
Oncotarget. 2017 Feb 21;8(8):13253-13263
pubmed: 28129648
Front Oncol. 2020 Mar 12;10:343
pubmed: 32226777
J Mol Diagn. 2014 Jul;16(4):418-30
pubmed: 24912849
Int J Biol Markers. 2011 Apr-Jun;26(2):117-23
pubmed: 21574151
Curr Opin Pulm Med. 2003 Jul;9(4):266-71
pubmed: 12806238
Nucleic Acids Res. 2010 Jul;38(Web Server issue):W214-20
pubmed: 20576703
Lab Chip. 2019 Jan 29;19(3):432-443
pubmed: 30604797
Bioscience. 2015 Aug 1;65(8):783-797
pubmed: 26955082
Curr Oncol Rep. 2018 Jul 20;20(9):70
pubmed: 30030656
Int J Mol Sci. 2019 Sep 05;20(18):
pubmed: 31491899
BMC Genomics. 2021 Jan 6;22(1):27
pubmed: 33407103
Cancers (Basel). 2019 Feb 21;11(2):
pubmed: 30795562
J Clin Oncol. 2012 May 1;30(13):1541-9
pubmed: 22412141
Methods. 2013 Jan;59(1):S1-6
pubmed: 23036329
Int J Clin Exp Med. 2015 Jun 15;8(6):9560-4
pubmed: 26309624
Sci Rep. 2016 Sep 08;6:32643
pubmed: 27605433
J Thorac Oncol. 2012 Dec;7(12):1858-1861
pubmed: 23154557
Int J Mol Sci. 2019 Apr 13;20(8):
pubmed: 31013896
Panminerva Med. 2020 Jan 30;:
pubmed: 32009350
FASEB J. 2018 Aug;32(8):4328-4342
pubmed: 29553831
J Thorac Oncol. 2012 Jul;7(7):1184-91
pubmed: 22617246
Pathol Int. 2014 Dec;64(12):607-12
pubmed: 25376377
Dis Markers. 2017;2017:9645940
pubmed: 28757678
Cancer Genomics Proteomics. 2017 Mar-Apr;14(2):103-117
pubmed: 28387650
PLoS One. 2017 May 4;12(5):e0176680
pubmed: 28472171
Noncoding RNA. 2019 Jun 17;5(2):
pubmed: 31212997
Am J Respir Cell Mol Biol. 2013 Dec;49(6):892-901
pubmed: 23885834
Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2238-46
pubmed: 20651076
BMC Genomics. 2007 Mar 01;8:62
pubmed: 17331233
J Oncol. 2019 Dec 23;2019:2902985
pubmed: 31929796
Methods Mol Biol. 2021;2174:143-170
pubmed: 32813249
Cell Mol Life Sci. 2018 Aug;75(15):2873-2886
pubmed: 29441425
CA Cancer J Clin. 2019 Sep;69(5):402-429
pubmed: 31283845
Front Oncol. 2020 Feb 07;10:105
pubmed: 32117755
Carcinogenesis. 2019 Nov 25;40(11):1320-1331
pubmed: 31169881
BMC Cancer. 2017 Nov 09;17(1):730
pubmed: 29121858
Sci Rep. 2020 Dec 7;10(1):21346
pubmed: 33288809
PLoS One. 2012;7(1):e30221
pubmed: 22253921
Cancer Epidemiol Biomarkers Prev. 2019 Jan;28(1):119-126
pubmed: 30257964
J Extracell Vesicles. 2013 May 27;2:
pubmed: 24009894
Occup Environ Med. 2017 Jun;74(6):456-463
pubmed: 28343162
Front Oncol. 2019 Nov 29;9:1293
pubmed: 31850200
Genes Chromosomes Cancer. 2012 Apr;51(4):409-18
pubmed: 22420032
Front Oncol. 2018 Dec 21;8:650
pubmed: 30622932
FEBS Lett. 2012 Jul 30;586(16):2382-8
pubmed: 22677169
Anticancer Res. 2015 Feb;35(2):719-27
pubmed: 25667451
Sci Rep. 2017 Jun 9;7(1):3140
pubmed: 28600498
BMC Cancer. 2015 Jul 09;15:510
pubmed: 26156324
World J Gastroenterol. 2020 May 28;26(20):2570-2583
pubmed: 32523312
Sci Rep. 2017 Apr 19;7:46537
pubmed: 28422153
Radiol Oncol. 2020 Mar 7;54(1):86-95
pubmed: 32187018
Eur Respir J. 2012 Jul;40(1):185-9
pubmed: 22135283
Crit Rev Oncol Hematol. 2020 Jun;150:102949
pubmed: 32330840
Sci Rep. 2017 Nov 10;7(1):15277
pubmed: 29127370
Biomed Pharmacother. 2018 Jun;102:203-211
pubmed: 29558717